SCHEMBL8937933

SCHEMBL8937933

Cc1cc2c(=O)[nH]ccc2cc1OC1CCN(Cc2ccncc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.54
MAP2K1 Q02750 1/20 0.44
PDE4B Q07343 1/20 0.41
SCN8A Q9UQD0 3/20 0.40
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
PRKACA P17612 3/20 0.39
PRKACG P22612 3/20 0.39
PRKACB P22694 3/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
SCN9A Q15858 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
SCN1A P35498 2/20 0.39
HTR1D P28221 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937943 0.90 ROCK1 (0.56) ROCK1MAP2K1SCN8AMAOAMAOB
SCHEMBL8937945 0.90 ROCK1 (0.56) ROCK1MAP2K1SCN8AMAOAMAOB
SCHEMBL8938179 0.89 MAP2K1 (0.57) ROCK1MAP2K1PDE4BSCN8APRKACA
SCHEMBL8937994 0.89 ROCK1 (0.55) ROCK1MAP2K1MAOAMAOBPRKACA
SCHEMBL8937973 0.89 ROCK1 (0.51) ROCK1SCN8AMAOAMAOBPRKACA
SCHEMBL8937925 0.88 ROCK1 (0.54) ROCK1MAP2K1MAOAMAOBPRKACA
SCHEMBL8937960 0.88 ROCK1 (0.52) ROCK1MAP2K1JAK2JAK1TYK2
SCHEMBL13890346 0.87 ROCK1 (0.53) ROCK1MAP2K1SCN8AMAOAMAOB
SCHEMBL8937993 0.86 ROCK1 (0.52) ROCK1MAP2K1SCN8AMAOAMAOB
SCHEMBL8937809 0.86 ROCK1 (0.52) ROCK1MAP2K1SCN8AJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885MAP2K1 1916/4885PDE4B 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.